Literature DB >> 22391248

LDL cholesterol: the lower the better.

Seth S Martin1, Roger S Blumenthal, Michael Miller.   

Abstract

High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391248     DOI: 10.1016/j.mcna.2012.01.009

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  17 in total

Review 1.  LDL cholesterol, statins and PCSK 9 inhibitors.

Authors:  Sanjiv Gupta
Journal:  Indian Heart J       Date:  2015-08-05

2.  PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.

Authors:  Kristopher J Swiger; Seth S Martin
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

3.  A nonsynonymous SNP in BANK1 is associated with serum LDL cholesterol levels in three Korean populations.

Authors:  Kyung-Won Hong; Jieun Lyu; So Hyun Lee; Bo Youl Choi; Sung Soo Kim; Yeonjung Kim
Journal:  J Hum Genet       Date:  2015-01-22       Impact factor: 3.172

Review 4.  Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 4.810

Review 5.  Lifestyle Factors and Coronary Artery Calcification.

Authors:  Chong-Do Lee; Sae Young Jae
Journal:  Pulse (Basel)       Date:  2015-03-12

6.  Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study.

Authors:  Jiangtao Lai; Bifeng Wu; Tianming Xuan; Zhong Liu; Junzhu Chen
Journal:  Lipids Health Dis       Date:  2014-01-02       Impact factor: 3.876

7.  Effects of blood lipid stability on progression of carotid atherosclerosis.

Authors:  Yu Ding; Bo Li; Feng Tian; Shanshan Zhou; Yundai Chen
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

8.  Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study.

Authors:  Jun Morinaga; Jiabin Zhao; Motoyoshi Endo; Tsuyoshi Kadomatsu; Keishi Miyata; Taichi Sugizaki; Yusuke Okadome; Zhe Tian; Haruki Horiguchi; Kazuya Miyashita; Nobuhiro Maruyama; Masashi Mukoyama; Yuichi Oike
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

9.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Authors:  Maryssa Canuel; Xiaowei Sun; Marie-Claude Asselin; Eustache Paramithiotis; Annik Prat; Nabil G Seidah
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

10.  Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.

Authors:  Veronique Verhoeven; Maja Lopez Hartmann; Roy Remmen; Johan Wens; Sandra Apers; Paul Van Royen
Journal:  BMC Complement Altern Med       Date:  2013-07-18       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.